McKesson Corporation
MCK
Peringkat dalam Saham
#187
McKesson Corporation is a prominent global provider of healthcare services,... McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
Harga Saham
$1,029.14
Kapitalisasi Pasar
$119.99B
Perubahan (1 hari)
1.73%
Perubahan (1 tahun)
30.63%
Negara
US
Perdagangan McKesson Corporation (MCK)
Kategori
Healthcare
Rasio P/E untuk McKesson Corporation (MCK)
Rasio P/E per October 2026 TTM: 26.02
Menurut laporan keuangan dan harga saham terbaru dari McKesson Corporation, rasio P/E saat ini (TTM) adalah 26.02. Pada akhir 2024, perusahaan memiliki rasio P/E sebesar 23.80.
Riwayat rasio P/E untuk McKesson Corporation dari 2000 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 26.02 | 0.00% |
| 2025 | 26.02 | 9.31% |
| 2024 | 23.80 | 68.68% |
| 2023 | 14.11 | -66.28% |
| 2022 | 41.85 | -706.47% |
| 2021 | -6.90 | -125.37% |
| 2020 | 27.20 | -96.04% |
| 2019 | 686.13 | 56.89% |
| 2018 | 437.33 | 6,817.88% |
| 2017 | 6.32 | -60.53% |
| 2016 | 16.02 | -54.95% |
| 2015 | 35.55 | 11.06% |
| 2014 | 32.01 | 68.89% |
| 2013 | 18.96 | 23.18% |
| 2012 | 15.39 | -14.73% |
| 2011 | 18.05 | 28.94% |
| 2010 | 14.00 | 19.55% |
| 2009 | 11.71 | -23.94% |
| 2008 | 15.39 | -15.02% |
| 2007 | 18.12 | -16.19% |
| 2006 | 21.61 | -130.58% |
| 2005 | -70.69 | -623.74% |
| 2004 | 13.50 | 3.94% |
| 2003 | 12.99 | -49.58% |
| 2002 | 25.75 | -116.43% |
| 2001 | -156.79 | -2,020.83% |
| 2000 | 8.16 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| - | - |
US
|
|
| 34.08 | 30.96% |
US
|
|
| - | - |
US
|
|
| 45.62 | 75.31% |
AU
|
|
| 24.73 | -4.97% |
US
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.